Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development

Science Translational Medicine

Volumn 5, Issue 204, 2013, Pages

  Imamovic, Lejla ^a   Sommer, Morten O A ^a,b  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b Chalmers University of Technology   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; CEFEPIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; MINOCYCLINE; NALIDIXIC ACID; NITROFURANTOIN; PIPERACILLIN; POLYMYXIN B; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; TIGECYCLINE; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG CHOICE; DRUG CYCLING; DRUG USE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUTATION;

EID: 84884680278     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006609     Document Type: Article

References (50)

1. A. D. Lopez, C. D. Mathers, M. Ezzati, C. J. L. Murray, D. T. Jamison, Global Burden of Disease and Risk Factors (The World Bank and Oxford Univ. Press, New York, 2006).
2. World Health Organization (WHO), Deaths Estimates for 2008 by Cause for WHO Member States (WHO Health Statistics and Information Systems, Geneva, 2011); http://www.who.int/healthinfo/global-burden-disease/estimates-country/en/index. html.
3. H. W. Boucher, G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg, J. Bartlett, Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
4. D. E. Goldberg, R. F. Siliciano, W. R. Jacobs Jr., Outwitting evolution: Fighting drug-resistant TB, malaria, and HIV. Cell 148, 1271-1283 (2012).
5. A. Pfaller, Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125, S3-S13 (2012).
6. M. Raviglione, B. Marais, K. Floyd, K. Lönnoroth, H. Getahun, G. B. Migliori, A. D. Harries, P. Nunn, C. Lienhardt, S. Graham, J. Chakaya, K. Weyer, S. Cole, S. H. E. Kaufmann, A. Zumla, Scaling up interventions to achieve global tuberculosis control: Progress and new developments. Lancet 379, 1902-1913 (2012).
7. European Centre for Disease Prevention and Control (ECDC) and European Medicines Agency (EMEA), The Bacterial Challenge: Time to React (Joint Technical Report EMEA/576176) (European Centre for Disease Prevention and Control, Stockholm, 2009); http://www.emea.europa.eu/docs/en-GB/document-library/Report/ 2009/11/WC500008770.pdf.
8. P. Borst, Cancer drug pan-resistance: Pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol. 2, 120066 (2012).
9. K. M. Pluchino, M. D. Hall, A. S. Goldsborough, R. Callaghan, M. M. Gottesman, Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98-105 (2012).
10. M. A. Fischbach, C. T. Walsh, Antibiotics for emerging pathogens. Science 325, 1089-1093 (2009).
11. L. L. Silver, Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71-109 (2011).
12. R. M. Gulick, J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, J. A. Chodakewitz, Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734-739 (1997).
13. F. Clavel, A. J. Hance, HIV drug resistance. N. Engl. J. Med. 350, 1023-1035 (2004).
14. M. A. Fischbach, Combination therapies for combating antimicrobial resistance. Curr. Opin. Microbiol. 14, 519-523 (2011).
15. P. Ball, Conclusions: The future of antimicrobial therapy - Augmentin and beyond. Int. J. Antimicrob. Agents 30 (Suppl. 2), S139-S141 (2007).
16. R. Chait, A. Craney, R. Kishony, Antibiotic interactions that select against resistance. Nature 446, 668-671 (2007).
17. C. A. Ohl, E. S. Dodds Ashley, Antimicrobial stewardship programs in community hospitals: The evidence base and case studies. Clin. Infect. Dis. 1, S23-S28 (2011).
18. C. B. Cunha, C. A. Varughese, E. Mylonakis, Antimicrobial stewardship programs (ASPs): The devil is in the details. Virulence 4, 147-149 (2013).
19. M. S. Niederman, Appropriate use of antimicrobial agents: Challenges and strategies for improvement. Crit. Care Med. 31, 608-616 (2003).
20. R. Masterton, Antibiotic cycling: More than it might seem? J. Antimicrob. Chemother. 55, 1-5 (2005).
21. A. M. Bal, A. Kumar, I. M. Gould, Antibiotic heterogeneity: From concept to practice. Ann. N. Y. Acad. Sci. 1213, 81-91 (2010).
22. D. I. Andersson, D. Hughes, Antibiotic resistance and its cost: Is it possible to reverse resistance? Nat. Rev. Microbiol. 8, 260-271 (2010).
23. P. Komp Lindgren, L. L. Marcusson, D. Sandvang, N. Frimodt-Møller, D. Hughes, Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob. Agents Chemother. 49, 2343-2351 (2005).
24. L. L. Marcusson, N. Frimodt-Møller, D. Hughes, Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog. 5, e1000541 (2009).
25. T. Luangtongkum, Z. Shen, V. W. Seng, O. Sahin, B. Jeon, P. Liu, Q. Zhang, Impaired fitness and transmission of macrolide-resistant Campylobacter jejuni in its natural host. Antimicrob. Agents Chemother. 56, 1300-1308 (2012).
26. S. Gagneux, C. D. Long, P. M. Small, T. Van, G. K. Schoolnik, B. J. Bohannan, The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312, 1944-1946 (2006).
27. A. Rodríguez-Rojas, M. D. Maciá, A. Couce, C. Gómez, A. Castañeda-García, A. Oliver, J. Blázquez, Assessing the emergence of resistance: The absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS One 5, e10193 (2010).
28. J. Björkman, I. Nagaev, O. G. Berg, D. Hughes, D. I. Andersson, Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287, 1479-1482 (2000).
29. M. Sundqvist, P. Geli, D. I. Andersson, M. Sjölund-Karlsson, A. Runehagen, H. Cars, K. Abelson-Storby, O. Cars, G. Kahlmeter, Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J. Antimicrob. Chemother. 65, 350-360 (2010).
30. E. M. Brown, D. Nathwani, Antibiotic cycling or rotation: A systematic review of the evidence of efficacy. J. Antimicrob. Chemother. 55, 6-9 (2005).
31. S. Sarraf-Yazdi, M. Sharpe, K. M. Bennett, T. L. Dotson, D. J. Anderson, S. N. Vaslef, A 9-year retrospective review of antibiotic cycling in a surgical intensive care unit. J. Surg. Res. 176, e73-e78 (2012).
32. D. K. Warren, H. A. Hill, L. R. Merz, M. H. Kollef, M. K. Hayden, V. J. Fraser, S. K. Fridkin, Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit. Care Med. 32, 2450-2456 (2004).
33. H. J. van Loon, M. R. Vriens, A. C. Fluit, A. Troelstra, C. van der Werken, J. Verhoef, M. J. Bonten, Antibiotic rotation and development of Gram-negative antibiotic resistance. Am. J. Respir. Crit. Care Med. 171, 480-487 (2005).
34. W. Szybalski, V. Bryson, Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J. Bacteriol. 64, 489-499 (1952).
35. C. Tamae, A. Liu, K. Kim, D. Sitz, J. Hong, E. Becket, A. Bui, P. Solaimani, K. P. Tran, H. Yang, J. H. Miller, Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. J. Bacteriol. 190, 5981-5988 (2008).
36. A. Liu, L. Tran, E. Becket, K. Lee, L. Chinn, E. Park, K. Tran, J. H. Miller, Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: Generating an antibiotic bar code. Antimicrob. Agents Chemother. 54, 1393-1403 (2010).
37. W. Szybalski, Genetic studies onmicrobial cross resistance to toxic agents. IV. Cross resistance of Bacillus megaterium to forty-four antimicrobial drugs. Appl. Microbiol. 2, 57-63 (1954).
38. K. P. Romano, A. Ali, C. Aydin, D. Soumana, A. Ozen, L. M. Deveau, C. Silver, H. Cao, A. Newton, C. J. Petropoulos, W. Huang, C. A. Schiffer, The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 8, e1002832 (2012).
39. M. J. Lee, A. S. Ye, A. K. Gardino, A. M. Heijink, P. K. Sorger, G. MacBeath, M. B. Yaffe, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
40. R. M. Klevens, J. R. Edwards, C. L. Richards Jr., T. C. Horan, R. P. Gaynes, D. A. Pollock, D. M. Cardo, Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 122, 160-166 (2007).
41. B. Allegranzi, S. Bagheri Nejad, C. Combescure, W. Graafmans, H. Attar, L. Donaldson, D. Pittet, Burden of endemic health-care-associated infection in developing countries: Systematic review and meta-analysis. Lancet 377, 228-241 (2011).
42. A. Y. Peleg, D. C. Hooper, Hospital-acquired infections due to Gram-negative bacteria. N. Engl. J. Med. 362, 1804-1813 (2010).
43. K. Drlica, X. Zhao, Mutant selection window hypothesis updated. Clin. Infect. Dis. 44, 681-688 (2007).
44. D. Hughes, D. I. Andersson, Selection of resistance at lethal and non-lethal antibiotic concentrations. Curr. Opin. Microbiol. 15, 555-560 (2012).
45. L. M. Grayson, A. Kucers, S. Crowe, J. McCarthy, J. Mills, J. Mouton, R. Norrby, D. Paterson, M. Pfaller, Kucers' the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic and Antiviral Drugs (Edward Arnold Ltd., London, ed. 6, 2010), vol. 1.
46. P. Imming, C. Sinning, A. Meyer, Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5, 821-834 (2006).
47. R. L. Gibson, J. L. Burns, B. W. Ramsey, Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168, 918-951 (2003).
48. A. G. Bosanquet, P. B. Bell, Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Blood 87, 1962-1971 (1996).
49. M. Polenakovic, L. Grcevska, S. Dzikova, 20 years after methylprednisolone/chlorambucil treatment in idiopathic membranous nephropathy stage II-III with nephrotic syndrome. Prilozi 27, 5-12 (2006).
50. 2 regulatory elements. Nucleic Acids Res. 25, 1203-1210 (1997).